ArticleNeoplasia (New York, N.Y.)2011

Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.

Sun-Jin Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.